Cargando…

Daily Dosing for Bedaquiline in Patients with Tuberculosis

The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are given QD. Using pharmacokinetic simulations, we explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Salinger, David H., Nedelman, Jerry R., Mendel, Carl, Spigelman, Melvin, Hermann, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811417/
https://www.ncbi.nlm.nih.gov/pubmed/31451504
http://dx.doi.org/10.1128/AAC.00463-19
_version_ 1783462470349750272
author Salinger, David H.
Nedelman, Jerry R.
Mendel, Carl
Spigelman, Melvin
Hermann, David J.
author_facet Salinger, David H.
Nedelman, Jerry R.
Mendel, Carl
Spigelman, Melvin
Hermann, David J.
author_sort Salinger, David H.
collection PubMed
description The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are given QD. Using pharmacokinetic simulations, we explored alternative QD bedaquiline regimens and determined that 200 mg QD for 8 weeks followed by 100 mg QD provides comparable exposures to the approved regimen. This simpler regimen is under clinical evaluation.
format Online
Article
Text
id pubmed-6811417
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-68114172019-11-07 Daily Dosing for Bedaquiline in Patients with Tuberculosis Salinger, David H. Nedelman, Jerry R. Mendel, Carl Spigelman, Melvin Hermann, David J. Antimicrob Agents Chemother Clinical Therapeutics The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are given QD. Using pharmacokinetic simulations, we explored alternative QD bedaquiline regimens and determined that 200 mg QD for 8 weeks followed by 100 mg QD provides comparable exposures to the approved regimen. This simpler regimen is under clinical evaluation. American Society for Microbiology 2019-10-22 /pmc/articles/PMC6811417/ /pubmed/31451504 http://dx.doi.org/10.1128/AAC.00463-19 Text en Copyright © 2019 Salinger et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Therapeutics
Salinger, David H.
Nedelman, Jerry R.
Mendel, Carl
Spigelman, Melvin
Hermann, David J.
Daily Dosing for Bedaquiline in Patients with Tuberculosis
title Daily Dosing for Bedaquiline in Patients with Tuberculosis
title_full Daily Dosing for Bedaquiline in Patients with Tuberculosis
title_fullStr Daily Dosing for Bedaquiline in Patients with Tuberculosis
title_full_unstemmed Daily Dosing for Bedaquiline in Patients with Tuberculosis
title_short Daily Dosing for Bedaquiline in Patients with Tuberculosis
title_sort daily dosing for bedaquiline in patients with tuberculosis
topic Clinical Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811417/
https://www.ncbi.nlm.nih.gov/pubmed/31451504
http://dx.doi.org/10.1128/AAC.00463-19
work_keys_str_mv AT salingerdavidh dailydosingforbedaquilineinpatientswithtuberculosis
AT nedelmanjerryr dailydosingforbedaquilineinpatientswithtuberculosis
AT mendelcarl dailydosingforbedaquilineinpatientswithtuberculosis
AT spigelmanmelvin dailydosingforbedaquilineinpatientswithtuberculosis
AT hermanndavidj dailydosingforbedaquilineinpatientswithtuberculosis